Palvella Therapeutics (FRA:PI6) Other Current Liabilities: €1.41 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PI6 Palvella Therapeutics Inc FRA:PI6
20 GF Score
Price €125.00
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Other Current Liabilities?

Palvella Therapeutics FRA:PI6 +1.63% 20 Other Current Liabilities is €1.41 Mil as of Mar. 2026. GuruFocus rates FRA:PI6 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Palvella Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was €1.41 Mil.

Palvella Therapeutics's quarterly other current liabilities increased from Sep. 2025 (€3.85 Mil) to Dec. 2025 (€4.11 Mil) but then declined from Dec. 2025 (€4.11 Mil) to Mar. 2026 (€1.41 Mil).

Palvella Therapeutics's annual other current liabilities increased from Dec. 2023 (€0.32 Mil) to Dec. 2024 (€5.96 Mil) but then declined from Dec. 2024 (€5.96 Mil) to Dec. 2025 (€4.11 Mil).

Palvella Therapeutics Other Current Liabilities Related Terms

Palvella Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Other Current Liabilities Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
0.87 0.32 5.96 4.11

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 3.20 3.85 4.11 1.41
FRA:PI6
20GF Score
Palvella Therapeutics Inc FRA:PI6
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €1.41 Mil mean?
Palvella Therapeutics (FRA:PI6) has a Other Current Liabilities of €1.41 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Palvella Therapeutics.
Is Palvella Therapeutics' Other Current Liabilities too high?
Palvella Therapeutics' current Other Current Liabilities is €1.41 Mil. Overall, Palvella Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Other Current Liabilities compare to GENB and NKTR?
Palvella Therapeutics' Other Current Liabilities of €1.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Palvella Therapeutics. Palvella Therapeutics's current Other Current Liabilities is €1.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (FRA:PI6) has a current Other Current Liabilities of €1.41 Mil. The current Other Current Liabilities is €1.41 Mil. Palvella Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Palvella Therapeutics (FRA:PI6), the current Other Current Liabilities is €1.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PVLA:USA
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
20GF Score

Get the complete analysis for FRA:PI6

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€125.00
Price